

Living Cell Technologies Ltd

Suite 2.11 / 737 Burwood Rd

Hawthorn VIC 3122

ABN: 14 104 028 042



Living Cell Technologies granted diabetes patent in the US

ASX Announcement – 5 July 2006

Living Cell Technologies (ASX:LCT) has received a Notice of Allowance for a US patent relating to methods of preparing transplantable neo-natal porcine islets, for the treatment of diabetes.

The patent, titled *Preparation and Xenotransplantation of Porcine Islets* (US 09/857325, Confirmation No 3318), extends LCT's coverage in treating type 1 diabetic patients with its DiabeCell product. The patent claims are to methods of preparing islets and the treatment of diabetes. Collectively these are broad patent claims for the treatment of diabetes using xenotransplantation (animal cell transplants).

This is the third US patent issued to LCT in the treatment of diabetes. The first two patents awarded to LCT covered porcine islet treatment and also the option to transplant porcine islets into diabetic patients without immunosuppression.

"It is a timely confirmation of the potential of our technology by the US Patent Office as we prepare to lodge our regulatory application for DiabeCell in the near future," said LCT CEO Mr Collinson.

"The age and preparation of the cells are a crucial factor in obtaining the best possible therapeutic outcome for cell therapy treatments," said Mr Collinson.

LCT is preparing to submit a regulatory application in the next quarter to New Zealand regulator MedSafe for clinical trials for its DiabeCell product for type 1 diabetes patients.

The patents add to LCT's significant suite of 8 patent families covering broad claims across major jurisdictions. The DiabeCell patents are granted in the US, New Zealand and Australian jurisdictions and are still being prosecuted in Europe.

The patent is assigned to LCT's IP holding subsidiary DiabeCell Pty Ltd. The patent will expire in 2022. A small fee will be paid to the United States Patent and Trademark Office by 6 September 2006 for the patent to be issued.

Outlook for 2006:

- Application for clinical trials of the DiabeCell product to NZ regulator MedSafe.
- Submission of Investigational New Drug (IND) application to the FDA for NeurotrophinCell.
- Further development of international pig production capabilities.

Further information:	
Paul Tan LCT Managing Director - NZ Tel: +64 9 270 7941 ptan@lctglobal.com	Paris Brooke General Manager LCT Tel: +61 3 9813 5501 pbrooke@lctglobal.com

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies Ltd (ASX: LCT) is an ASX listed, vertically integrated cell therapy company, operating globally through offices in Australia, New Zealand and the United States. LCT focuses on the injection of healthy living cells to replace, repair, or regenerate diseased or damaged tissues, which does not require the use of toxic drugs to prevent rejection. The company product portfolio focuses on treatments for Huntington's disease / stroke / ALS, insulin dependent diabetes and haemophilia.